ClinicaliQ Trial Snapshot
- A Study to Identify Breast Cancer (IDBC) — Recruiting • Oncology • NCT04495244.
- What is being tested: A novel blood-based diagnostic test (Syantra DX Breast Cancer) designed to identify breast cancer through biomarker detection in blood samples, offering a non-invasive alternative to traditional imaging and tissue biopsy methods.
- Patient eligibility overview: The study recruits women with suspected or confirmed breast cancer alongside control populations without breast cancer, enabling validation of the test's sensitivity and specificity across diverse clinical presentations.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based…
Eligibility Snapshot
- * Aged 30-75 years * Normal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography * Women with suspected Invasive Breast Cancer * Individuals with an abnormal or suspicious mammogram * Abnormal screening mammogram with suspected benign breast disease or proliferative changes
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.